| Title | Circulating adiponectin levels in various malignancies: an updated meta-analysis of 107 studies |
| Authors | Wei, Tai Ye, Peng Peng, Xin Wu, Li-Ling Yu, Guang-Yan |
| Affiliation | Peking Univ, Dept Oral & Maxillofacial Surg, Sch & Hosp Stomatol, Beijing, Peoples R China. Peking Univ, Key Lab Mol Cardiovasc Sci, Hlth Sci Ctr, Dept Physiol & Pathophysiol,Minist Educ, Beijing, Peoples R China. Beijing Key Lab Cardiovasc Receptors Res, Beijing, Peoples R China. Peking Univ, Dept Oral & Maxillofacial Surg, Sch & Hosp Stomatol, Beijing, Peoples R China. Wu, LL (reprint author), Peking Univ, Key Lab Mol Cardiovasc Sci, Hlth Sci Ctr, Dept Physiol & Pathophysiol,Minist Educ, Beijing, Peoples R China. Wu, LL (reprint author), Beijing Key Lab Cardiovasc Receptors Res, Beijing, Peoples R China. |
| Keywords | adiponectin malignancy biomarker diagnosis meta-analysis MOLECULAR-WEIGHT ADIPONECTIN ENDOMETRIAL CANCER-RISK POSTMENOPAUSAL BREAST-CANCER VISCERAL FAT ACCUMULATION RENAL-CELL CARCINOMA NON-HODGKIN-LYMPHOMA COLORECTAL-CANCER PLASMA ADIPONECTIN SERUM ADIPONECTIN PROSTATE-CANCER |
| Issue Date | 2016 |
| Publisher | ONCOTARGET |
| Citation | ONCOTARGET.2016,7(30),48671-48691. |
| Abstract | Early detection of cancers is challenging for lack of specific biomarkers. Adiponectin is an adipokine predominantly derived from adipocytes and hypoadiponectinemia has been reported to associate with risk of many types of cancers. However, available evidence is controversial. Some studies show that increased adiponectin levels correlate with cancer risk. Therefore, we performed a meta-analysis of the association between circulating adiponectin levels and cancer development. A systematic search of PubMed, EMBASE, Wiley Online Library and Cochrane Library was conducted for eligible studies involving circulating adiponectin and malignancies from inception to August 8, 2015. Standard mean differences (SMDs) with 95% confidence intervals (95% CIs) were calculated by use of a random-effect model. Funnel plot and Egger's linear regression test were conducted to examine the risk of publication bias. 107 studies were included with 19,319 cases and 25,675 controls. The pooled analysis indicated that circulating adiponectin levels were lower in patients with various cancers than in controls, with a pooled SMD of -0.334 mu g/ml (95% CI, -0.465 to -0.203, P = 0.000). No evidence of publication bias was observed. Circulating high molecular weight adiponectin levels were also lower in cancer patients than in controls, with a pooled SMD of -0.502 mu g/ml (95% CI, -0.957 to -0.047, P = 0.000). This meta-analysis provides further evidence that decreased adiponectin levels is associated with risk of various cancers. Hypoadiponectinemia may represent a useful biomarker for early detection of cancers. |
| URI | http://hdl.handle.net/20.500.11897/433947 |
| ISSN | 1949-2553 |
| DOI | 10.18632/oncotarget.8932 |
| Indexed | SCI(E) PubMed |
| Appears in Collections: | 口腔医院 分子心血管学教育部重点实验室 |
